maresyl 1 mg/ml pršilo za nos, raztopina
jadran - galenski laboratorij, d.o.o. ljubljana - ksilometazolin - pršilo za nos, raztopina - ksilometazolin 0,87 mg / 1 ml - ksilometazolin
ambisome 50 mg prašek za koncentrat ra raztopino za infundiranje
gilead sciences international limited - amfotericin b - prašek za raztopino za infundiranje - amfotericin b 50 mg / 1 viala - amfotericin b
ambisome liposomal 50 mg prašek za koncentrat za disperzijo za infundiranje
gilead sciences international limited - amfotericin b - prašek za koncentrat za disperzijo za infundiranje - amfotericin b 50 mg / 1 viala - amfotericin b
maresyl 0,5 mg/ml pršilo za nos, raztopina
jadran - galenski laboratorij, d.o.o. ljubljana - ksilometazolin - pršilo za nos, raztopina - ksilometazolin 0,43 mg / 1 ml - ksilometazolin
omnipaque 300 mg i/ml raztopina za injiciranje
ge healthcare as - jod - raztopina za injiciranje - jod 300 mg / 1 ml joheksol - joheksol
omnipaque 350 mg i/ml raztopina za injiciranje
ge healthcare as - jod - raztopina za injiciranje - jod 350 mg / 1 ml - joheksol
omnipaque 350 mg i/ml raztopina za injiciranje
ge healthcare as - jod - raztopina za injiciranje - jod 350 mg / 1 ml joheksol - joheksol
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresivi - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.